[Cutaneous lymphomas].
Cutaneous lymphoma is a heterogenous entity regarding clinical and pathological features, evolutive profiles and prognosis, molecular abnormalities and response to therapy. Recent classification is based on these specificities, giving a major concern to the prognostic implications of these different entities. While treatment is effective and prognosis is favorable in low grade forms, recent therapeutic innovations relying on the use of biological tools are likely to improve the prognosis of the most severe ones, as it is the case for anti-CD20 monoclonal antibodies (rituximab) in disseminated cutaneous B-cell lymphomas, and anti-CD52 monoclonal antibody (alemtuzumab) in refractory forms of cutaneous T-cell lymphoma. The deciphering of key molecular mechanisms underlying these malignancies should open new therapeutic perspectives in a close future.